Q-omics provides the consensus-scored HADHAP2 profile across patient tissues and cancer cell-line models. HADHAP2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, HADHAP2 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, HADHAP2 RNA expression shows 15,859 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, BRCA, and TGCT as cancer lineages where HADHAP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HADHAP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HADHAP2 survival associations across molecular data types. HADHAP2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HADHAP2 RNA expression–survival associations across cancer types. High HADHAP2 expression shows unfavorable associations in MESO, ACC and OV, but favorable associations in SKCM, LUSC and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for HADHAP2 RNA expression.
This table summarizes HADHAP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HADHAP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HADHAP2 shows lower tumor expression in BRCA, BLCA and THCA and higher tumor expression in HNSC, COAD and READ. The BRCA box plot shows higher HADHAP2 RNA expression in normal versus tumor tissue (log2 FC = −0.350, t-test p < 0.001).
This table shows molecular features associated with HADHAP2 in patient tissues and cancer cell lines. In patient samples, HADHAP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
